• Home
• Videos
• Investment Research
• Hot Stock Confidential
• Tours and Conferences

Subscribe

GTXI: TFN’s prostate drug pick is up 12% on Phase 2 trial news

Posted July 31, 2008

Our prostate drug play GTXI surges after heavy volume spike!

by J. Christoph Amberger

Baltimore — (TFN): On April 2, 2008, in a story called “Profit Opportunity: A diamond in a mud pit,” our own Andrew Snyder recommended GTx Inc. (GTXI) when the stock was trading at $16.36.

Today, the stock was trading at $18.45. This represents a gain of almost 13%. The catalyst for the latest surge was news that the company was continuing Phase III clinical trial of toremifene in 20-milligram doses to prevent prostate cancer in men with a type of tissue lesion called prostatic intraepithelial neoplasia.

Full results of the study are expected for the summer of 2009.

We say hang on to your shares for the time being! But sell if the stock falls back to $18!

****Make sure you sign up for our FREE TFN News Feed for breaking news, special reports and new financial videos. Sign up through your favorite reader here. Or, if you prefer, have the feed delivered to your email.

Related Articles

• United Airlines (UAUA) recovers from rumor-driven crash - September 8, 2008
• Expect Maximum Market Volatility - October 30, 2008
• Hot Stock Confidential takes 41% on Nymox (NYMX) and 28% profits on Synta (SNTA) in under 4 weeks - August 13, 2008
• Eagle Bulk Shipping (NASDAQ:EGLE), Navios Maritime (NYSE:NM), China Cosco (OTC:CICOF) represent great entry levels into the bulk shipping boom - June 10, 2008
• eBay (NASDAQ:EBAY) takes advantage of online spending - December 4, 2008

Comments

blog comments powered by Disqus

Advertisement

TFN Stock Tools

Indices: US-World | Most Actives

Stock Quotes & News